Literature DB >> 33459646

Low Liver Enzymes and Risk of Dementia: The Atherosclerosis Risk in Communities (ARIC) Study.

Yifei Lu1, James R Pike2, Elizabeth Selvin3, Thomas Mosley4, Priya Palta5,6, A Richey Sharrett7, Alvin Thomas1, Laura Loehr8, A Sidney Barritt9, Ron C Hoogeveen10, Gerardo Heiss1.   

Abstract

BACKGROUND: Low levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the low physiologic range, surrogate markers for reduced liver metabolic function, are associated with cerebral hypometabolism, impairment in neurotransmitter production and synaptic maintenance, and a higher prevalence of dementia. It is unknown whether a prospective association exists between low liver enzyme levels and incident dementia.
OBJECTIVE: To determine whether low levels of ALT and AST are associated with higher risk of incident dementia.
METHODS: Plasma ALT and AST were measured on 10,100 study participants (mean age 63.2 years, 55% female, 22% black) in 1996-1998. Dementia was ascertained from comprehensive neuropsychological assessments, annual contact, and medical record surveillance. Cox proportional hazards regression was used to estimate the association.
RESULTS: During a median follow-up of 18.3 years (maximum 21.9 years), 1,857 individuals developed dementia. Adjusted for demographic factors, incidence rates of dementia were higher at the lower levels of ALT and AST. Compared to the second quintile, ALT values <10th percentile were associated with a higher risk of dementia (hazard ratio [HR] 1.34, 95% CI 1.08-1.65). The corresponding HR was 1.22 (0.99-1.51) for AST.
CONCLUSION: Plasma aminotransferases <10th percentile of the physiologic range at mid-life, particularly ALT, were associated with greater long-term risk of dementia, advocating for attention to the putative role of hepatic function in the pathogenesis of dementia.

Entities:  

Keywords:  ALT; AST; Alzheimer’s disease; dementia; liver hypometabolism

Mesh:

Substances:

Year:  2021        PMID: 33459646      PMCID: PMC8679120          DOI: 10.3233/JAD-201241

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.160


  39 in total

1.  Blood brain barrier: the role of pyridoxine.

Authors:  Atmaram Yarlagadda; Anita H Clayton
Journal:  Psychiatry (Edgmont)       Date:  2007-08

2.  Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Gaetano Piccinocchi; Roberto Piccinocchi; Emiliano Schena; Giovanni Galati; Antonio De Vincentis; Chiara Dell'Unto; Antonio Picardi
Journal:  Dig Liver Dis       Date:  2014-06-19       Impact factor: 4.088

3.  Association of low alanine aminotransferase with loss of independence or death: A 5-year population-based cohort study.

Authors:  Hajime Yamazaki; Tsukasa Kamitani; Takeshi Matsui; Yosuke Yamamoto; Shunichi Fukuhara
Journal:  J Gastroenterol Hepatol       Date:  2019-02-27       Impact factor: 4.029

4.  Modifiable Risk Factors and Prevention of Dementia: What Is the Latest Evidence?

Authors:  Kristine Yaffe
Journal:  JAMA Intern Med       Date:  2018-02-01       Impact factor: 21.873

5.  Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort.

Authors:  Alvaro Alonso; Jeffrey R Misialek; Mohamed A Amiin; Ron C Hoogeveen; Lin Y Chen; Sunil K Agarwal; Laura R Loehr; Elsayed Z Soliman; Elizabeth Selvin
Journal:  Heart       Date:  2014-06-12       Impact factor: 5.994

6.  ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

Authors:  Paul Y Kwo; Stanley M Cohen; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2016-12-20       Impact factor: 10.864

Review 7.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged.

Authors:  Suzanne Craft
Journal:  Arch Neurol       Date:  2009-03

Review 8.  Neuro-transmitters in the central nervous system & their implication in learning and memory processes.

Authors:  Helton J Reis; Cristina Guatimosim; Maryse Paquet; Magda Santos; Fabíola M Ribeiro; Arthur Kummer; Grace Schenatto; João V Salgado; Luciene B Vieira; Antônio L Teixeira; András Palotás
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

9.  Amyloid-β efflux from the central nervous system into the plasma.

Authors:  Kaleigh Filisa Roberts; Donald L Elbert; Tom P Kasten; Bruce W Patterson; Wendy C Sigurdson; Rose E Connors; Vitaliy Ovod; Ling Y Munsell; Kwasi G Mawuenyega; Michelle M Miller-Thomas; Christopher J Moran; Dewitte T Cross; Colin P Derdeyn; Randall J Bateman
Journal:  Ann Neurol       Date:  2014-10-24       Impact factor: 10.422

10.  Tissue-Specific Metabolomics Analysis Identifies the Liver as a Major Organ of Metabolic Disorders in Amyloid Precursor Protein/Presenilin 1 Mice of Alzheimer's Disease.

Authors:  Hong Zheng; Aimin Cai; Qi Shu; Yan Niu; Pengtao Xu; Chen Li; Li Lin; Hongchang Gao
Journal:  J Proteome Res       Date:  2019-01-09       Impact factor: 4.466

View more
  2 in total

1.  Machine Learning Analysis Reveals Biomarkers for the Detection of Neurological Diseases.

Authors:  Simon Lam; Muhammad Arif; Xiya Song; Mathias Uhlén; Adil Mardinoglu
Journal:  Front Mol Neurosci       Date:  2022-05-31       Impact factor: 6.261

2.  Serum clinical laboratory tests and risk of incident dementia: a prospective cohort study of 407,190 individuals.

Authors:  Xiao-Yu He; Kevin Kuo; Liu Yang; Ya-Ru Zhang; Bang-Sheng Wu; Shi-Dong Chen; Wei Cheng; Jian-Feng Feng; Jin-Tai Yu
Journal:  Transl Psychiatry       Date:  2022-08-04       Impact factor: 7.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.